Skip to main content

Table 2 Time-to-event analyses: Cox PH models of mortality and hospitalization

From: Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysis

 

Death

Hospitalization

 

Adjusted hazard ratio

p-value

Adjusted hazard ratio

p-value

Azacitidinea

0.721

(0.008)**

0.787

(0.020)*

Age

1.031

(0.000)**

0.999

(0.818)

Gender Male

1.522

(0.001)**

1.097

(0.372)

Prior Diagnosis of MDSb

0.878

(0.283)

1.131

(0.225)

Charlson comorbidity index scorec

0.937

(0.088)

1.001

(0.974)

Prior RBC transfusiond

1.373

(0.018)*

1.321

(0.012)*

Medicare Advantage enrolleee

0.973

(0.855)

0.993

(0.954)

Prior Hospitalizationf

1.303

(0.069)

1.061

(0.618)

Observations

487

 

487

 
  1. p-values in parentheses.
  2. *significant at 5%; ** significant at 1%.
  3. Reference groups: adecitabine, bno diagnosis of MDS in the 6 months prior to starting treatment with a demethylating agent, cCharlson comorbidity index is a continuous score from 0 to 24 (most comorbidity burden), dno RBC transfusion in 6 months prior to starting treatment with a demethylating agent, ecommerical insurance, fno hospitalizations in 6 months prior to starting treatment with a demethylating agent.
Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us